Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Huntington’s Disease Market Revenue Growth On Track For A 17.5% CAGR Through 2030
The Huntington’s disease market has demonstrated significant expansion in recent years. It is anticipated to increase from $0.55 billion in 2025 to $0.64 billion in 2026, achieving a compound annual growth rate (CAGR) of 17.9%. This historical growth can be attributed to the discovery of the htt gene mutation, the limited access to curative treatments, increasing awareness of rare neurodegenerative diseases, the reliance on symptomatic therapies, and the rise in diagnosis through genetic testing.
The huntington’s disease market size is anticipated to experience significant expansion over the next few years. It is projected to reach $1.22 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 17.5%. This growth during the forecast period is driven by progress in gene therapy and RNA-based treatments, increased investment in rare disease research, an expanding clinical pipeline for disease-modifying therapies, a growing emphasis on early intervention strategies, and enhanced support from patient advocacy organizations. Key trends expected in this period include a heightened focus on disease-modifying and gene silencing therapies, wider adoption of genetic testing for early and accurate diagnosis, a rising emphasis on multidisciplinary approaches to symptom management, the expansion of clinical trials targeting neurodegenerative disorders, and the increasing implementation of patient-centric care models and home-based management.
Get A Free Sample Report With In-Depth Market Insights:
Huntington’s Disease Market Development Factors: What’s Supporting Demand?
An increasing occurrence of neurological conditions is anticipated to drive the expansion of the huntington’s disease market in the future. These disorders are health issues impacting the brain, spinal cord, and nerves, resulting in symptoms like difficulties with movement, coordination, sensation, or cognitive functions. The rise in neurological disorders can be linked to elements like older populations, environmental poisons, shifts in lifestyle, enhanced diagnostic abilities, and genetic susceptibilities, all contributing to the detection and identification of a greater number of cases. Huntington’s disease, specifically, is a neurodegenerative condition resulting from a genetic alteration, characterized by motor impairment, a decrease in cognitive abilities, and psychiatric manifestations, which deteriorate progressively. For example, in March 2023, data from the Alzheimer’s Association, a US-based nonprofit voluntary health organization, indicated that approximately 6.7 million Americans aged 65 and above are currently living with Alzheimer’s dementia. Should there be no significant medical advancements to prevent, delay, or cure this ailment, this figure could increase to 13.8 million by 2060. Consequently, the growing occurrence of neurological conditions is fueling the expansion of the huntington’s disease market.
Huntington’s Disease Market Segmentation And Category Overview
The huntington’s disease market covered in this report is segmented –
1) By Treatment Type: Symptomatic Therapy, Disease-Modifying Therapy, Other Treatment Types
2) By Diagnosis: Magnetic Resonance Imaging (MRI), Genetic Testing
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Symptomatic Therapy: Antipsychotics, Antidepressants, Mood Stabilizers, Muscle Relaxants
2) By Disease-Modifying Therapy: Gene Silencing Therapies, Neuroprotective Agents
3) By Other Treatment Types: Physical Therapy, Occupational Therapy, Speech Therapy
Huntington’s Disease Market Transformation Trends: What Innovations Are Driving Change?
Leading companies operating within the Huntington’s disease market are prioritizing the development of innovative solutions, such as oral small molecule drugs, designed to manage symptoms and slow the disease’s progression. An oral small molecule drug is a low-molecular-weight compound that can be taken by mouth and is formulated to interact with specific biological targets, including proteins or enzymes, to treat diseases. For example, in September 2024, PTC Therapeutics Inc., a US-based pharmaceutical company, was granted Fast Track designation by the U.S. Food and Drug Administration (USFDA) for its PTC518 program, which targets Huntington’s disease. This designation is provided for therapies that address significant unmet medical needs, emphasizing PTC518’s potential as a disease-modifying treatment for patients living with this genetic disorder.
Huntington’s Disease Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the huntington’s disease market are Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Apotex Inc, Ipsen S.A., Vertex Pharmaceuticals Incorporated, H. Lundbeck A/S, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Lupin Limited., Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc, PTC Therapeutics Inc., Annexon Inc., Voyager Therapeutics Inc., Stealth BioTherapeutics Corp., Vaccinex Inc., SOM Biotech S.L., Alterity Therapeutics Limited, Medesis pharma SA.
View The Full Huntington’s Disease Market Report:
Huntington’s Disease Market Largest Region: Which Geography Holds The Biggest Share?
North America was the largest region in the huntington’s disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington’s disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
